Skip to main content
search

News & Events

News

2023-09-13

BRIM closes a $45.8 million rights issue early to accelerate its pipeline of regenerative peptides
2023-06-28

Taiwan has ambitions to make biotech ‘second industry’ after semi-conductors
2023-05-09

BRIM plans to launch a new funding round to accelerate late-stage clinical trial and initiate a new phase 2 trial for orphan drug BRM424 in the U.S
2023-04-18

BRM421, a new drug for treating Dry Eye Disease, receives approval to proceed to Phase 2 clinical trials in China
2023-04-06

BRIM submits US IND for BRM424 Phase 2 study treating neurotrophic keratitis
2023-03-02

BRIM Biotechnology announces first patient enrollment in pivotal Phase 3 clinical trial of BRM421 for Dry Eye Disease
2023-02-23

Novel regenerative peptide therapy for dry eye disease, BRM421, advances to Phase 3 clinical trials
2023-02-20

BRIM Biotechnology strengthens leadership team in preparation for transformational year ahead
2022-12-08

BRIM Biotechnology receives FDA Orphan Drug Designation for BRM424 to treat neurotrophic keratitis
2022-12-01

BRIM Biotechnology, Inc. raises $20 million in Series E funding round
Close Menu